anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
During the first month, participants will be in a month-long control wash in period where no intervention will be provided. During the second month, participants will be in a 4-week daily IMT intervention period. During the third month, participants will be in a month-long efficacy period with no intervention provided.
This study aims to compare the mechanical strength of three different posterior-based internal fixation methods for posteromedial tibial plateau fractures. The study utilized 12 tibial plateaus harvested from fresh-frozen cadavers, and the posteromedial fracture fragments were created. The bones were then randomly assigned to one of three fixation methods: two posteroanterior lag screws (LS) size 4.0 mm, posterior buttress plate using a 3.5 mm small dynamic compression plate (DCP), or posterior buttress plate using a 3.5 mm T-shaped plate (TP). Biomechanical testing was performed by applying vertical compression force to the center of the posteromedial fracture fragment until the load to failure (displacement ≥ 3 mm) was reached, and displacement of the fragment was measured using a motion sensor. The data exhibited normal distribution, and one-way analysis of variance (ANOVA) was used to determine the load to failure, followed by Fisher post hoc Least-Significant Difference (LSD) to correct for multiple comparisons. The statistical analysis demonstrated significantly higher mean load to failure values in the T-shaped plate group compared to both the small dynamic compression plate group and the lag screw group (p < 0.05). However, after conducting further post hoc analysis, the observed significant differences were solely between the LS and TP groups (p = 0.021). These findings suggest that the T-shaped plate represents the most effective method for internally fixing posteromedial tibial plateau fractures.
NEW MATERIAL:The substituted phenylacetic acid derivative of formulaI(R1 and R2 are H or lower alkyl; n is 1-3) and its salt. EXAMPLE:2-[4-(2-Hydroxycyclohexylidenemethyl)phenyl]prioponic acid. USE:It has antiphlogistic, analgesic and antipyretic acetivities and is useful as a medicine. It can be administered orally or to the colon in the form of suppository, or can be applied topically as pointment, cream, etc. PROCESS:The compound of formulaIcan be prepared by reducing the enonecarboxylic acid derivative of formula II. The reducing agent is preferably an alkyli metal borohydride compound such as sodium borohydride, sodium cyanoborohydride, etc., and the solvent is an organic solvent such as ethyl ether. The reaction is carried out usually under ice cooling - heating at the boiling point of the solvent.
Identifying substances (I) that regulate urinary incontinence and the urge to urinate comprising incubating a test compound (X) with a cell and/or cell preparation that has synthesized a specific protein (Y) of the PIM kinase family, and measuring either binding of (X) to (Y) or a functional parameter that is altered by the binding, is new. Identifying substances (I) that regulate urinary incontinence and the urge to urinate comprising: (a) incubating a test compound (X) with a cell and/or cell preparation that has synthesized a specific protein (Y) of the PIM kinase family; and (b) measuring either binding of (X) to (Y) or a functional parameter that is altered by such binding. (Y) is: (a) PIM-1 or -3 kinase; (b) any of five proteins (Y1) of 313, 313, 326, 326 or 326 amino acids (aa), reproduced, or proteins at least 90 % similar to them; (c) a protein encoded by either any of five nucleic acid sequences (Z) of 1301, 942, 1176, 2133 or 2477 nucleotides (nt), reproduced; or by sequences with at least 90 % similarity, or by sequences that bind under stringent conditions to these sequences or their antisense polynucleotides; or (d) a fragment of at least 10 aa from any of the specified proteins. Independent claims are also included for: (1) (I) identified by the new method; and (2) use of specific PIM related materials (A) for treatment (including by gene therapy), diagnosis and/or activity testing of urinary incontinence or the urge to urinate. ACTIVITY : Uropathic. No details of tests for uropathic activity are given. MECHANISM OF ACTION : Regulating activity or expression of PIM kinases that are involved in bladder control; gene therapy.
PCT No. PCT/US91/09100 Sec. 371 Date Jun. 4, 1993 Sec. 102(e) Date Jun. 4, 1993 PCT Filed Dec. 4, 1991Disclosed are methods and compositions for the suppression of expression of the neu oncogene, as well as suppression of neu oncogene-mediated transformation, tumorigenesis and metastasis. The method disclosed involved introduction of adenovirus early 1A gene (the E1A gene) products into affected cells. These products, which are preferably introduced by transfection of the E1A gene into affected cells, serve to suppress neu gene expression as measured by a reduction of p185 expression. Furthermore, the E1A gene products surprisingly serve to suppress the oncogenic phenotype, as indicated by a reduction in cell growth, growth in soft agar, as well as tumorigenic and metastatic potential in vivo. The inventors propose that E1A gene products, or derivatives therefrom, may ultimately be employed a treatment modalities for neu-mediated cancers, such as cancers of the female genital tract and breast.
A patient movement monitoring system for a bed mattress having a first side, a second side, a head end side and a foot end. The system includes a first sensing device coupled at the first side of the bed mattress, a second sensing device coupled at the second side of the bed mattress, and a third sensing device coupled at the head end side of the bed mattress. The sensing devices each include an accelerometer, gyroscope, and vibration sensor. The accelerometer detects an intensity of patient movement in the bed mattress. The gyroscope detects a change in the angle of the bed mattress. The vibration sensor detects vibration of the bed mattress. And a pressure sensing array is coupled at the underside of the bed mattress to detect changes in pressure of the bed mattress. A processing device is in electronic communication with the sensing devices and pressure sensing array and generates an alert if the sensors don't detect patient movement within a predetermined time period.
INTRODUCTION: Ciprofol is a new intravenous anesthetic with a similar chemical structure to propofol. We aimed to compare the incidence of adverse actions like injection pain and time indexes of ciprofol versus propofol on anesthesia in patients undergoing endoscopy. We also compared anesthetists' satisfaction during the procedure.
METHODS: Two independent researchers (Liu and Zeng) searched the Cochrane Library, Embase databases, and PubMed for controlled clinical trials. This meta-analysis of randomized controlled trials (RCTs) was performed with the Review Manager, Stata and the Cochrane Risk-of-Bias 2 tool to evaluate methodological quality. Relative risks with 95% confidence interval (CI) were calculated for outcomes.
RESULTS: Ten trials, including 1545 patients, were examined in the current meta-analysis. During anesthesia in patients undergoing endoscopy, the incidence of injection pain was significantly reduced in the research group. Compared with propofol, the pooled risk difference (RD) with the use of ciprofol for injection pain for all the procedures was - 0.34 (95% confidence interval [CI], -0.48 to 0.19), and RR for hypotension was 0.73(95% CI:0.58 to 0.92). GRADE showed this meta-analysis has moderate or low confidence. Trial sequential analysis for mortality indicated insufficient sample size for a definitive judgment for lower incidence of hypotension.
CONCLUSION: In painless endoscopy, compared with propofol, ciprofol exhibited non-inferiority anesthesia/sedation in patients, and had a good safety profile with a lower incidence of pain on injection and may reduce the chance of hypotension. Trial sequential analysis suggested the need for more cases, and GRADE highlighted moderate certainty, emphasizing the necessity for further targeted RCTs.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42023433627.
A 70-year-old male came to our clinic with a high fever and left scrotal swelling. Following a diagnosis of left-side epididymitis, antibiotic treatment was started, though the swelling did not improve. Since an additional examination revealed an abscess in the left scrotum, scrotal incision and drainage were performed. Although the symptoms subsided, urine outflow from the incision was observed. The patient then noted that he had inserted a glass ball into the urethral meatus when he was about 30 years old. It was considered that an abscess and fistula had formed due to inflammation caused by the foreign body. Thus a transurethral surgical procedure was used for crushing and removal. The fistula disappeared within three months after the operation and the patient has not been affected by dysuria since that time. Symptoms may appear several years following insertion of a foreign body into the urethra. To the best of our knowledge, the present case is the longest term of indwelling, approximately 40 years, following insertion of a foreign body reported in Japan.
Participants will wear a biosensor (Fitbit Charge HR®) continuously for a period of 15 days and respond to PROMIS questionnaires. This is not a chemotherapy or treatment-intervention trial.
Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for 4 cycles (2 pre-surgery, 2 post-surgery) in the absence of disease progression or unacceptable toxicity. Patients may optionally undergo blood sample collection on study.
Medication-related osteonecrosis of the jaw (MRONJ) is an intractable adverse event. Dental implants are one of the triggering factors of MRONJ, and implant therapy with low MRONJ risk is required. This study aimed to investigate a rat model of MRONJ induced by extraoral placement of titanium materials and the use of mesenchymal stromal cell (MSCs) sheets to prevent MRONJ. Eight-week-old male rats were administered zoledronate and dexamethasone thrice weekly until killing. A week after drug initiation, a titanium screw and a plate were placed on the left buccal side of the mandible. Allogeneic bone marrow-derived MSC sheets were co-grafted with the titanium plates in the MSC sheet ( +) group. Six weeks after titanium placement, the rats were killed, and their excised mandibular bones were subjected to micro-computed tomography (CT) analysis. Histological analysis was performed after the titanium implants were removed. Empty lacunae visualized on hematoxylin and eosin staining were used as evidence of bone necrosis. Bone necrosis was reduced in the MSC sheet ( +) group. Tartrate-resistant acid phosphatase (TRAP) staining revealed a decreased number of TRAP-positive cells in areas with a large number of empty lacunae in the MSC sheet (-) group. Micro-CT analyses demonstrated that the bone volume fraction (BV/TV) was not significantly different between the MSC sheet (-) and ( +) groups. We conclude that MRONJ can be triggered by a titanium placement in rats, and grafting of allogeneic MSC sheets has the potential to prevent MRONJ.
Patients with tumors that do not match one of the currently active drug-biomarker combinations randomized to Arm I receive anti-B7H1 monoclonal antibody MEDI4736 IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.
Neck pain is a musculoskeletal system disorder that causes social and economic loss by reducing the quality of life (QOL) of the individual, and its prevalence varies from 16.7 to 75.1% in the adult population. Non-specific neck pain (NNP) is a symptom related to a postural or mechanical cause. NNP is also associated with loss of cervical curvature. In healthy spines, the axial load along the cervical spine is supported along the ventral column of the spine. However, in spines with the loss of lordosis, the load moves more anteriorly, which causes neck pain. Cervical exercise has been shown to be an effective treatment for neck pain and cervical alignment, but there is still a need for more clinical trials evaluating the effectiveness of the exercise approach. It seems reasonable to assume that naturally good neck muscle strength and range of motion are likely to be protective factors against neck pain.

As per previous research, the effects of exercise therapy on non-specific neck pain have been examined but there is limited literature available for use of cervical and shoulder retraction exercises in patients with nonspecific neck pain. Most of the studies have been done with neck isometrics, manual mobilization, and deep cervical flexors training and there is less scope of practicing cervical extension traction in contrast with modified cervical and shoulder retraction exercises. Previous research is limited by no use of a control group in a modified retraction exercise regime. To fill this literature gap this study is proposed which will focus on the clinical significance of modified cervical and shoulder retraction exercises on pain, disability, and Cobb's angle in the management of non-specific neck pain.
It's referred to a continuous fluid treatment chamber designed for pulsed electric field or radio frequency electric field. It's a chamber with two metal hollow tubes and isolating ring. Isolating ring is between two metal hollow tubes which are connected with high intensive pulse or radio frequency generator respectively. The main characteristics are as follow: In two metal hollow tubes near the isolating ring there is at least one metal conductor or lead. With this chamber, the capacity can be greatly improved (the material can pass through any large diameter tube, not sew). And the electric field distribution can be more uniform and the treatment of fluid will be highly efficient. It's benefit for pulse electric field or radio frequency electric field to be applied in industry.
EPIDIOLEX can cause somnolence and sedation. In controlled studies for LGS and DS (10 and 20 mg/kg/day dosages), the incidence of somnolence and sedation (including lethargy) was 32% in EPIDIOLEX-treated patients (27% and 34% of patients taking EPIDIOLEX 10 or 20 mg/kg/day, respectively), compared with 11% in patients on placebo and was generally dose-related. The rate was higher in patients on concomitant clobazam (46% in EPIDIOLEX-treated patients taking clobazam compared with 16% in EPIDIOLEX-treated patients not on clobazam). In the controlled study for TSC, the incidence of somnolence and sedation (including lethargy) was 19% in EPIDIOLEX-treated patients (25 mg/kg/day), compared with 17% in patients on placebo. The rate was higher in patients on concomitant clobazam (33% in EPIDIOLEX-treated patients taking clobazam compared with 14% in EPIDIOLEX-treated patients not on clobazam). In general, these effects were more common early in treatment and may diminish with continued treatment. Other CNS depressants, including alcohol, could potentiate the somnolence and sedation effect of EPIDIOLEX. Prescribers should monitor patients for somnolence and sedation and should advise patients not to drive or operate machinery until they have gained sufficient experience on EPIDIOLEX to gauge whether it adversely affects their ability to drive or operate machinery.
Renal impairment, including minimal change disease, acute and chronic interstitial nephritis, and renal failure have been reported in patients given products that contain mesalamine or are converted to mesalamine. In animal studies, the kidney was the principal organ of mesalamine toxicity. 

Evaluate the risks and benefits of using Mesalamine Rectal Suspension Enema in patients with known renal impairment or a history of renal disease or taking concomitant nephrotoxic drugs. Mesalamine is known to be substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function. Evaluate renal function in all patients prior to initiation and periodically while on Mesalamine Rectal Suspension Enema therapy. Discontinue Mesalamine Rectal Suspension Enema if renal function deteriorates while on therapy.
PROBLEM TO BE SOLVED: To produce a synthetic maci strongly coloring blue by synthesizing the synthetic mica containing titanium in a reductive atmosphere. SOLUTION: A fluoromica such as fluorophlogopite, fluoro-4-silicon mica, fluorotenorite and these isomorphous substitution product is appropriately used as the synthetic mica. Either of melting synthesis, hydrothermal synthesis, solid- phase reaction, etc., may be good as a production method itself of the synthetic mica, but the melting synthesis is preferable since crystalinity is good, and either of crucible method and inner heat type melting method is good, and the synthesis is executed at about 1300-1600 deg.C. The titanium is blended at the time of melting a production starting material of the synthetic mica, and its content is kept in 1-15wt.% according to a concn. of blue to be obtained.  The reductive atmosphere is required at the time of melting the production starting material of the synthetic mica, but it is good if a reductive gas is injected at the time of melting and a reducing agent such as carbon, Rochelle salt and stannous oxide is added, and it is good if a carbon electrode is used at the inner heat type melting method.
Dopamine is a neurotransmitter involved in oxygen sensing and control of reflex hyperventilation. In aquatic vertebrates, oxygen sensing occurs in the gills via chemoreceptive neuroepithelial cells (NECs), but a mechanism for dopamine in autonomic control of ventilation has not been defined. We used immunohistochemistry and confocal microscopy to map the distribution of tyrosine hydroxylase (TH), an enzyme necessary for dopamine synthesis, in the gills of zebrafish. TH was found in nerve fibers of the gill filaments and respiratory lamellae. We further identified dopamine active transporter (dat) and vesicular monoamine transporter (vmat2) expression in neurons of the gill filaments using transgenic lines. Moreover, TH- and dat-positive nerve fibers innervated NECs. In chemical screening assays, domperidone, a D2 receptor antagonist, increased ventilation frequency in zebrafish larvae in a dose-dependent manner. When larvae were confronted with acute hypoxia, the D2 agonist, quinpirole, abolished the hyperventilatory response. Quantitative polymerase chain reaction confirmed expression of drd2a and drd2b (genes encoding D2 receptors) in the gills, and their relative abundance decreased following acclimation to hypoxia for 48 h. We localized D2 receptor immunoreactivity to NECs in the efferent gill filament epithelium, and a novel cell type in the afferent filament epithelium. We provide evidence for the synthesis and storage of dopamine by sensory nerve terminals that innervate NECs. We further suggest that D2 receptors on presynaptic NECs provide a feedback mechanism that attenuates the chemoreceptor response to hypoxia. Our studies suggest that a fundamental, modulatory role for dopamine in oxygen sensing arose early in vertebrate evolution.
This invention provides potent HCV neutralizing monoclonal antibodies and portions thereof that inhibit entry of HCV into susceptible cells. The neutralizing monoclonal antibodies of the invention are broadly reactive against HCV of different genotypes, including genotypes 1 and 2. A particular monoclonal antibody, designated PA-29, does not bind soluble or independently-expressed HCV E1 and E2 envelope glycoproteins. A hybridoma cell line producing the PA-29 monoclonal antibody has been deposited under ATCC Accession No. PTA-7632. The described monoclonal antibodies, including PA-29 and humanized and chimeric forms thereof, serve as HCV antagonists for use in therapeutic and prophylactic methods of treating and preventing HIV infection of susceptible cells, in methods of blocking HCV entry into susceptible cells and in methods of diagnosis and detection of HCV in a sample of a subject and within a subject.
Participants undergo MRI over 45 minutes at baseline. Participants then receive hyperpolarized carbon C 13 pyruvate IV over 30-40 seconds. Within 1 minute, participants undergo MRSI over 3 minutes and MRI over 10 minutes.
The present invention relates to a novel method for correcting presbyopia or tired eyes. The method is based on a mechanism for inducing a mathematical formula in the anterior surface radio of the cornea, which is different from that inherited by people and useful for providing them with the required vision at all distances without constantly using spectacles. The aforementioned process consists in producing a compound myopic astigmatism having a vertical axis. The following methods are useful for changing the curve of the cornea: 1) using a moulding lens after a refractive surgical technique, either Lasik, Lasek, PRK or any process in which the anterior layers of the cornea or sclera have undertaken a surgery, or any process that alters the refraction of the eyeball; 2) using a moulding contact lens and a boosting substance in drops, gel or the like when the inherited defect of refraction is moderated -6.00 gradations or less, or when the defect is reduced -3.00 gradations or less; 3 ) when the inherited refraction defect does not require optical correction for looking from far, but having indicia that the physiological process of presbyopia is occurring; 4) using the Dynamic and Interactive technique (DI) which alters the normal physiology of the cornea as well as the visual memory. Dynamical changes of the corneal and body physiology are induced according to the working needs and/or age variations presented during the natural process of the presbyopia. The method of the invention dynamically allows the corneal physiology to be altered without generating irreversible changes or anatomo-hystological complications in the eye. The corneal power is based on the fine and accurate perception of the images produced by the motor-brain-optical system MBOS. Said method includes a computer program which uses the following complete formula: CA (cerebral adaptation) + VM (visual memory) + OAS (Optical-anterior system) + MBOS (Motor-brain-optical system) so as to individualize the corneal power for both eyes. The technique of the method includes special designs of the moulding lens as well as boosting substances in drops, gel or the like, which promote changes in the collagen fibers, the hyaluronic acid, the percentage of corneal hydration and the normal parameters in the anatomy-histology and physiology of the cornea.
We present the case of a 60-year-old male, with active smoking and cocaine use disorder, who reported progressive chest pain. Various anatomical and functional cardiac imaging, performed to further evaluate chest pain etiology, revealed changing severity and distribution of left main artery (LMA) stenosis, raising suspicion for vasospasm. Intracoronary nitroglycerin relieved the vasospasm, with resolution of the LMA pseudostenosis. A diagnosis of vasospastic angina (VA) led to starting appropriate medical therapy with lifestyle modification counselling. This case highlights VA, a frequently underdiagnosed etiology of angina pectoris. We discuss when to suspect VA, its appropriate work-up, and management.